Johnson & Johnson $JNJ Shares Purchased by Asset Planning Services Inc. LA ADV

Asset Planning Services Inc. LA ADV lifted its position in Johnson & Johnson (NYSE:JNJ) by 1.0% in the second quarter, Holdings Channel reports. The firm owned 37,639 shares of the company’s stock after acquiring an additional 365 shares during the period. Johnson & Johnson accounts for approximately 2.6% of Asset Planning Services Inc. LA ADV’s holdings, making the stock its 18th biggest position. Asset Planning Services Inc. LA ADV’s holdings in Johnson & Johnson were worth $5,749,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Investors Asset Management of Georgia Inc. GA ADV boosted its position in shares of Johnson & Johnson by 1.3% in the 2nd quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 9,126 shares of the company’s stock valued at $1,394,000 after purchasing an additional 116 shares during the period. AWM Capital LLC boosted its position in shares of Johnson & Johnson by 3.3% in the 2nd quarter. AWM Capital LLC now owns 3,222 shares of the company’s stock valued at $492,000 after purchasing an additional 103 shares during the period. Autumn Glory Partners LLC boosted its position in shares of Johnson & Johnson by 6.9% in the 2nd quarter. Autumn Glory Partners LLC now owns 23,835 shares of the company’s stock valued at $3,641,000 after purchasing an additional 1,548 shares during the period. PUREfi Wealth LLC boosted its position in shares of Johnson & Johnson by 21.5% in the 2nd quarter. PUREfi Wealth LLC now owns 8,548 shares of the company’s stock valued at $1,306,000 after purchasing an additional 1,514 shares during the period. Finally, Sendero Wealth Management LLC boosted its position in shares of Johnson & Johnson by 4.2% in the 2nd quarter. Sendero Wealth Management LLC now owns 8,353 shares of the company’s stock valued at $1,276,000 after purchasing an additional 337 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. UBS Group set a $198.00 price objective on Johnson & Johnson in a research report on Friday. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. HSBC increased their price objective on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Finally, Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $189.88.

Johnson & Johnson Stock Up 0.4%

JNJ opened at $188.95 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business has a 50 day simple moving average of $177.04 and a 200-day simple moving average of $163.18. The stock has a market capitalization of $455.06 billion, a P/E ratio of 20.21, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.92.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.